Fusion Protein Inhibitors [MoA] class drugs

3 results

  • beyfortus - nirsevimab injection

    (Nirsevimab)
    Sanofi Pasteur Inc.
    Beyfortus prevents RSV lower respiratory tract disease in neonates and infants during their first RSV season, and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
    Medication Details
    Drug Interactions

  • synagis - palivizumab injection, solution

    (Palivizumab)
    Swedish Orphan Biovitrum Ab (Publ)
    Synagis prevents serious lower respiratory tract disease caused by RSV in pediatric patients: premature infants (≤35 weeks gestation, ≤6 months old), or children ≤24 months with bronchopulmonary dysplasia requiring treatment, or hemodynamically significant congenital heart disease. Not indicated for RSV treatment.
    Medication Details
    Drug Interactions